1020 STONY HILL ROAD, YARDLEY, PA
Market cap: $97.2M (5/20/2025)
Price: $9.60
Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies
Shareholder votes
Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
.2VOTING AND SUPPORT AGREEMENT
To Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE in Chronic Rhinosinusitis (CRS)
Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
News, Articles of Incorporation
News
Q1
Amended Annual Report
FY 2024
Q3
Q2
FY 2023
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Additional Proxy Materials
Definitive Merger Proxy Statement
Notification Filed by a National Security Exchange
Statement of Changes in Beneficial Ownership
S-8 POS